330 related articles for article (PubMed ID: 12012315)
1. Arsenic trioxide: mechanisms of action.
Davison K; Mann KK; Miller WH
Semin Hematol; 2002 Apr; 39(2 Suppl 1):3-7. PubMed ID: 12012315
[TBL] [Abstract][Full Text] [Related]
2. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms of the antileukemia activities of retinoid and arsenic.
Nitto T; Sawaki K
J Pharmacol Sci; 2014; 126(3):179-85. PubMed ID: 25319615
[TBL] [Abstract][Full Text] [Related]
4. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy.
Huan SY; Yang CH; Chen YC
Leuk Lymphoma; 2000 Jul; 38(3-4):283-93. PubMed ID: 10830735
[TBL] [Abstract][Full Text] [Related]
5. Understanding the molecular pathogenesis of acute promyelocytic leukemia.
Lo-Coco F; Hasan SK
Best Pract Res Clin Haematol; 2014 Mar; 27(1):3-9. PubMed ID: 24907012
[TBL] [Abstract][Full Text] [Related]
6. Acute promyelocytic leukemia: cellular and molecular basis of differentiation and apoptosis.
Chen Z; Wang ZY; Chen SJ
Pharmacol Ther; 1997; 76(1-3):141-9. PubMed ID: 9535176
[TBL] [Abstract][Full Text] [Related]
7. Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide.
Shepshelovich D; Oniashvili N; Parnes D; Klein A; Muchtar E; Yeshaya J; Aviram A; Rabizadeh E; Raanani P
Cancer Genet; 2015 Nov; 208(11):575-9. PubMed ID: 26471811
[TBL] [Abstract][Full Text] [Related]
8. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells.
Chen GQ; Shi XG; Tang W; Xiong SM; Zhu J; Cai X; Han ZG; Ni JH; Shi GY; Jia PM; Liu MM; He KL; Niu C; Ma J; Zhang P; Zhang TD; Paul P; Naoe T; Kitamura K; Miller W; Waxman S; Wang ZY; de The H; Chen SJ; Chen Z
Blood; 1997 May; 89(9):3345-53. PubMed ID: 9129041
[TBL] [Abstract][Full Text] [Related]
9. Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines.
Davison K; Côté S; Mader S; Miller WH
Leukemia; 2003 May; 17(5):931-40. PubMed ID: 12750708
[TBL] [Abstract][Full Text] [Related]
10. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins.
Chen GQ; Zhu J; Shi XG; Ni JH; Zhong HJ; Si GY; Jin XL; Tang W; Li XS; Xong SM; Shen ZX; Sun GL; Ma J; Zhang P; Zhang TD; Gazin C; Naoe T; Chen SJ; Wang ZY; Chen Z
Blood; 1996 Aug; 88(3):1052-61. PubMed ID: 8704214
[TBL] [Abstract][Full Text] [Related]
11. Targeting HDAC3 to overcome the resistance to ATRA or arsenic in acute promyelocytic leukemia through ubiquitination and degradation of PML-RARα.
Dai B; Wang F; Wang Y; Zhu J; Li Y; Zhang T; Zhao L; Wang L; Gao W; Li J; Zhu H; Li K; Hu J
Cell Death Differ; 2023 May; 30(5):1320-1333. PubMed ID: 36894687
[TBL] [Abstract][Full Text] [Related]
12. All-trans retinoic acid and arsenic trioxide fail to derepress the monocytic differentiation driver Irf8 in acute promyelocytic leukemia cells.
Liu X; Chen J; Yu S; Yan L; Guo H; Dai J; Zhang W; Zhu J
Cell Death Dis; 2017 May; 8(5):e2782. PubMed ID: 28492552
[TBL] [Abstract][Full Text] [Related]
13. Relapsed APL patient with variant NPM-RARalpha fusion responded to arsenic trioxide-based therapy and achieved long-term survival.
Chen Y; Gu L; Zhou C; Wu X; Gao J; Li Q; Zhu Y; Jia C; Ma Z
Int J Hematol; 2010 May; 91(4):708-10. PubMed ID: 20405253
[TBL] [Abstract][Full Text] [Related]
14. Acute promyelocytic leukemia: a paradigm for differentiation therapy.
Grimwade D; Mistry AR; Solomon E; Guidez F
Cancer Treat Res; 2010; 145():219-35. PubMed ID: 20306254
[TBL] [Abstract][Full Text] [Related]
15. [Basic and clinical studies of the gene product-targeting therapy based on leukemogenesis--editorial].
Chen SJ; Chen LJ; Zhou GB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Feb; 13(1):1-8. PubMed ID: 15748426
[TBL] [Abstract][Full Text] [Related]
16. What is the role of arsenic in newly diagnosed APL?
Tallman MS
Best Pract Res Clin Haematol; 2008 Dec; 21(4):659-66. PubMed ID: 19041605
[TBL] [Abstract][Full Text] [Related]
17. Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies.
Chou WC; Dang CV
Curr Opin Hematol; 2005 Jan; 12(1):1-6. PubMed ID: 15604884
[TBL] [Abstract][Full Text] [Related]
18. Molecular targets of arsenic trioxide in malignant cells.
Miller WH
Oncologist; 2002; 7 Suppl 1():14-9. PubMed ID: 11961205
[TBL] [Abstract][Full Text] [Related]
19. New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation.
Kitamura K; Kiyoi H; Yoshida H; Tobita T; Takeshita A; Ohno R; Naoe T
Cancer Chemother Pharmacol; 1997; 40 Suppl():S36-41. PubMed ID: 9272132
[TBL] [Abstract][Full Text] [Related]
20. The impact of molecularly targeted therapies upon the understanding of leukemogenesis and the role of hematopoietic stem cell transplantation in acute promyelocytic leukemia.
Nagai S; Takahashi T; Kurokawa M
Curr Stem Cell Res Ther; 2010 Dec; 5(4):372-8. PubMed ID: 20528759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]